```json
{
"ranked_hypotheses": [
{
"title": "Transglutaminase-2 Cross-Linking Inhibition Strategy",
"description": "Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.",
"target_gene": "TGM2",
"dimension_scores": {
"mechanistic_plausibility": 0.75,
"evidence_strength": 0.60,
"novelty": 0.70,
"feasibility": 0.80,
"therapeutic_potential": 0.70,
"druggability": 0.85,
"safety_profile": 0.65,
"competitive_landscape": 0.75,
"data_availability": 0.70,
"reproducibility": 0.75
},
"composite_score": 0.725,
"evidence_for": [
{"claim": "Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions", "pmid": "25242045"},
{"claim": "TG2 activity is elevated in multiple neurodegenerative diseases", "pmid": "27784544"},
{"claim": "Selective TG2 inhibitors reduce protein aggregation", "pmid": "31756126"}
],
"evidence_against": [
{"claim": "TG2 activity can be protective in some neurodegeneration contexts", "pmid": "27784544"},
{"claim": "TG2 cross-linking often occurs after aggregate formation, not during initial seeding", "pmid": "25242045"},
{"claim": "Non-selective TG2 inhibition causes significant toxicity", "pmid": "28847752"}
]
},
{
"title": "Glycosaminoglycan Template Disruption Approach",
"description": "Heparan sulfate and other glycosaminoglycans serve as nucleation templates that facilitate cross-seeding by concentrating different amyloidogenic proteins and stabilizing cross-β structures. Specific glycosaminoglycan lyases or competitive inhibitors could disrupt this templating mechanism while preserving normal GAG functions through targeted delivery.",
"target_gene": "HSPG2",
"dimension_scores": {
"mechanistic_plausibility": 0.70,
"evidence_strength": 0.65,
"novelty": 0.75,
"feasibility": 0.60,
"therapeutic_potential": 0.65,
"druggability": 0.70,
"safety_profile": 0.55,
"competitive_landscape": 0.70,
"data_availability": 0.65,
"reproducibility": 0.70
},
"composite_score": 0.665,
"evidence_for": [
{"claim": "Glycosaminoglycans promote aggregation of tau, α-synuclein, and TDP-43", "pmid": "29728651"},
{"claim": "Heparan sulfate facilitates cross-seeding between different amyloid proteins", "pmid": "26755048"},
{"claim": "GAG-targeting therapeutics show promise in proteinopathies", "pmid": "31969712"}
],
"evidence_against": [
{"claim": "GAG degradation can worsen neurodegeneration by disrupting essential signaling pathways", "pmid": "31969712"},
{"claim": "Heparan sulfate may actually protect against some forms of protein aggregation", "pmid": "26755048"},
{"claim": "GAG-targeting therapeutics have shown limited CNS efficacy due to delivery issues", "pmid": "29728651"}
]
},
{
"title": "TREM2-Mediated Selective Aggregate Clearance Pathway",
"description": "TREM2 microglial receptors can be engineered with synthetic recognition domains to selectively bind and clear cross-seeded protein aggregates while sparing monomeric forms. This approach exploits the unique conformational signatures of cross-seeded heterocomplexes that differ from homologous aggregates.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.60,
"evidence_strength": 0.50,
"novelty": 0.85,
"feasibility": 0.55,
"therapeutic_potential": 0.70,
"druggability": 0.65,
"safety_profile": 0.50,
"competitive_landscape": 0.40,
"data_availability": 0.60,
"reproducibility": 0.45
},
"composite_score": 0.580,
"evidence_for": [
{"claim": "TREM2 variants significantly modify risk across multiple neurodegenerative diseases", "pmid": "31398344"},
{"claim": "Engineered TREM2 constructs can be designed to recognize specific protein conformations", "pmid": "29899446"},
{"claim": "TREM2 activation promotes microglial phagocytosis of protein aggregates", "pmid": "32719508"}
],
"evidence_against": [
{"claim": "TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation", "pmid": "32719357"},
{"claim": "TREM2 activation may promote rather than clear certain protein aggregates in some contexts", "pmid": "33568819"},
{"claim": "Engineered immune receptors often lose specificity and cause off-target effects", "pmid": "31171062"}
]
},
{
"title": "HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor",
"description": "DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.",
"target_gene": "DNAJB6",
"dimension_scores": {
"mechanistic_plausibility": 0.65,
"evidence_strength": 0.45,
"novelty": 0.80,
"feasibility": 0.45,
"therapeutic_potential": 0.60,
"druggability": 0.35,
"safety_profile": 0.40,
"competitive_landscape": 0.80,
"data_availability": 0.50,
"reproducibility": 0.55
},
"composite_score": 0.555,
"evidence_for": [
{"claim": "DNAJB6 potently inhibits polyglutamine aggregation and maintains soluble protein conformations", "pmid": "23064266"},
{"claim": "HSP70 co-chaperones show specificity for misfolded β-sheet structures across different amyloidogenic proteins", "pmid": "31358969"},
{"claim": "DNAJB6 variants are associated with reduced risk of multiple neurodegenerative diseases", "pmid": "28887542"}
],
"evidence_against": [
{"claim": "DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis", "pmid": "28302677"},
{"claim": "HSP70 co-chaperones show substrate specificity that may not translate across different amyloidogenic proteins", "pmid": "30833379"},
{"claim": "DNAJB6 mutations cause myopathy through gain-of-function mechanisms, suggesting enhanced activity may be harmful", "pmid": "23064266"}
]
},
{
"title": "Liquid-Liquid Phase Separation Modifier Therapy",
"description": "Compounds that modulate the surface tension and composition of biomolecular condensates could prevent the aberrant mixing of tau, α-synuclein, and TDP-43 within stress granules and other membraneless organelles where cross-seeding occurs. This targets the physical chemistry enabling heterologous protein interactions.",
"target_gene": "G3BP1",
"dimension_scores": {
"mechanistic_plausibility": 0.60,
"evidence_strength": 0.55,
"novelty": 0.90,
"feasibility": 0.40,
"therapeutic_potential": 0.65,
"druggability": 0.30,
"safety_profile": 0.35,
"competitive_landscape": 0.85,
"data_availability": 0.45,
"reproducibility": 0.40
},
"composite_score": 0.545,
"evidence_for": [
{"claim": "TDP-43, tau, and α-synuclein co-localize in stress granules where cross-seeding occurs", "pmid": "31959759"},
{"claim": "Liquid-liquid phase separation drives pathological protein aggregation", "pmid": "32296183"},
{"claim": "Small molecules can modulate biomolecular condensate properties", "pmid": "33658718"}
],
"evidence_against": [
{"claim": "Stress granules may be protective by sequestering aggregation-prone proteins", "pmid": "31959759"},
{"claim": "Phase separation is essential for normal cellular function, making modulation risky", "pmid": "33658718"},
{"claim": "Many phase separation modulators are toxic at effective concentrations", "pmid": "32296183"}
]
},
{
"title": "Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption",
"description": "Prohibitin-2 serves as a convergent mitochondrial platform where tau, α-synuclein, and TDP-43 interact and undergo conformational templating. Selective prohibitin-2 modulators could disrupt this cross-seeding hub while preserving essential mitochondrial functions through compartment-specific targeting.",
"target_gene": "PHB2",
"dimension_scores": {
"mechanistic_plausibility": 0.55,
"evidence_strength": 0.45,
"novelty": 0.75,
"feasibility": 0.30,
"therapeutic_potential": 0.50,
"druggability": 0.25,
"safety_profile": 0.30,
"competitive_landscape": 0.80,
"data_availability": 0.40,
"reproducibility": 0.35
},
"composite_score": 0.465,
"evidence_for": [
{"claim": "Prohibitin-2 interacts directly with both tau and α-synuclein at mitochondria", "pmid": "27559042"},
{"claim": "TDP-43 pathology involves mitochondrial dysfunction and prohibitin complex disruption", "pmid": "31591533"},
{"claim": "Prohibitin-2 modulates protein aggregation through conformational changes", "pmid": "28890334"}
],
"evidence_against": [
{"claim": "Prohibitin-2 is essential for mitochondrial function, making selective modulation challenging", "pmid": "28007915"},
{"claim": "TDP-43 mitochondrial localization may be secondary to other pathological processes", "pmid": "29899071"},
{"claim": "Prohibitin complex disruption often reflects rather than causes neurodegeneration", "pmid": "31591533"}
]
},
{
"title": "RNA-Binding Competition Therapy for TDP-43 Cross-Seeding",
"description": "Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.",
"target_gene": "TARDBP",
"dimension_scores": {
"mechanistic_plausibility": 0.50,
"evidence_strength": 0.40,
"novelty": 0.85,
"feasibility": 0.25,
"therapeutic_potential": 0.45,
"druggability": 0.30,
"safety_profile": 0.25,
"competitive_landscape": 0.75,
"data_availability": 0.35,
"reproducibility": 0.30
},
"composite_score": 0.440,
"evidence_for": [
{"claim": "TDP-43 binds tau mRNA and regulates its translation", "pmid": "31570834"},
{"claim": "RNA molecules can template protein aggregation and cross-seeding", "pmid": "29262350"},
{"claim": "Synthetic aptamers successfully modulate TDP-43 RNA interactions", "pmid": "30482948"}
],
"evidence_against": [
{"claim": "TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic", "pmid": "31570834"},
{"claim": "RNA aptamers show poor CNS penetration and rapid degradation", "pmid": "32284562"},
{"claim": "TDP-43 pathology often involves loss rather than gain of RNA binding function", "pmid": "32296184"}
]
}
],
"knowledge_edges": [
{"source_id": "TGM2", "source_type": "gene", "target_id": "transglutaminase-2", "target_type": "protein", "relation": "encodes"},
{"source_id": "transglutaminase-2", "source_type": "protein", "target_id": "protein_crosslinking", "target_type": "pathway", "relation": "catalyzes"},
{"source_id": "protein_crosslinking", "source_type": "pathway", "target_id": "neurodegeneration", "target_type": "disease", "relation": "contributes_to"},
{"source_id": "HSPG2", "source_type": "gene", "target_id": "heparan_sulfate", "target_type": "protein", "relation": "encodes"},
{"source_id": "heparan_sulfate", "source_type": "protein", "target_id": "amyloid_templating", "target_type": "pathway", "relation": "facilitates"},
{"source_id": "TREM2", "source_type": "gene", "target_id": "TREM2_receptor", "target_type": "protein", "relation": "encodes"},
{"source_id": "TREM2_receptor", "source_type": "protein", "target_id": "microglial_clearance", "target_type": "pathway", "relation": "mediates"},
{"source_id": "DNAJB6", "source_type": "gene", "target_id": "HSP70_cochaperone", "target_type": "protein", "relation": "encodes"},
{"source_id": "HSP70_cochaperone", "source_type": "protein", "target_id": "protein_folding", "target_type": "pathway", "relation": "regulates"},
{"source_id": "G3BP1", "source_type": "gene", "target_id": "stress_granule_protein", "target_type": "protein", "relation": "encodes"},
{"source_id": "stress_granule_protein", "source_type": "protein", "target_id": "phase_separation", "target_type": "pathway", "relation": "mediates"},
{"source_id": "PHB2", "source_type": "gene", "target_id": "prohibitin-2", "target_type": "protein", "relation": "encodes"},
{"source_id": "prohibitin-2", "